top of page

The Team

Who We Are

Erik Vinther - CEO of Kripthonite Therapeutics

Erik Vinther

Co-founder & CEO

Erik Vinther is CEO and co-founder of Kripthonite Therapeutics. He holds a Master's degree in economics from Aarhus University and has worked as an executive commercial strategist at Novo Nordisk leading several major projects from development to launch. He is passionate about creating innovative solutions for unmet medical needs and improving the lives of patients.

  • LinkedIn

Kristian Mark Jacobsen, PhD

Chief Scientific Officer

Kristian Mark Jacobsen, our CSO and co-founder, brings a wealth of knowledge from his time as a postdoc at the Department of Chemistry at Aarhus University. His pioneering research on PH1154, elucidated its potential to combat hypoxic cancer cells, with unparalleled efficacy. Kristian’s dedication to innovation and his relentless pursuit of progress makes him an invaluable asset to our team.

  • LinkedIn
Kristian Mark Jacobsen - CSO of Kripthonite Therapeutics
Per Hjerrild - CTO of Kripthonite Therapeutics

Per Hjerrild, PhD

Chief Technology Officer

Per Hjerrild, a synthetic chemist by training, is co-founder and Chief Technology Officer of Kripthonite Therapeutics. He played a pivotal role in the synthetic development of PH1154, a groundbreaking drug substance that targets hypoxic cancer cells. His expertise in cancer research and dedication to innovation continues to drive Kripthonite Therapeutics’ mission to develop precision weapons against cancer.

  • LinkedIn

Charlotte Dyring

Co-founder & COO

Our COO Charlotte Dyring is a senior executive who has successfully led a start-up biotech company to become a Nasdaq-listed CRO. She has expertise in running companies, developing cell lines and processes, and managing HR. She is a remarkable leader and a valuable asset to the biotech industry.

  • LinkedIn
Charlotte Dyring.jfif

Our advisory board

Advisor - Thomas Poulsen

Thomas Poulsen

Co-founder and Chief Advisor

Professor Thomas Bjørnskov Poulsen is a distinguished researcher and innovator.

Thomas' lab focus on developing bioactive substances with novel mechanisms of action.

​

Thomas is the brain behind the new class of hypoxia-targeting that form the basis of Kripthonite.

​

His work is pivotal in the fight against hypoxic cancer.

Advisor - Peter Horn Møller

Peter Horn Møller

Co-founder and head of IPR strategy

Peter Horn Møller, a seasoned life science entrepreneur and patent strategist.

​

With a solid track record of transforming state-of-the-art science into protected products, his expertise lies in IP strategy and licensing.

 

His entrepreneurial journey includes key roles in Albumedix’s spin-out from Novozymes and co-founding Zyneyro.

Per thor Straten

Per thor Straten

​

Advisor in immuno-oncology

Per thor Straten is a professor of immunology and microbiology at the University of Copenhagen and the director of the Center for Cancer Immunotherapy at the University Hospital Herlev in Denmark.

​

He is a pioneer and leader in the field of cancer immunology and immunotherapy, and has co-founded several biotech companies and holds patents on peptide antigens. He is also involved in several international research projects and networks on immunotherapy, and has published numerous scientific papers on his field of interest.

Advisor - Mike Horsman

Michael R. Horsman

Advisor in preclinical development

Michael is Professor of Experimental Radiotherapy at Aarhus University and a pioneer in the field of tumor microenvironment and hypoxia.

 

His groundbreaking work includes the discovery of nicotinamide’s role in preventing acute hypoxia and its potential combination with chronic hypoxia-targeting therapies.

 

His vast knowledge of tumor hypoxia, radiation and hypoxia-targeting strategies is extremely useful for Kripthonite.

bottom of page